Rubius Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Rubius Therapeutics generated cash of -$150,142,000, which is less than the previous year. Cash used in financing activities reached the amount of -$75,470,000 last year. Net change in cash is therefore -$212,668,000.
Cash Flow
| 2016 | -9.50M | -443K | 15.41M |
|---|---|---|---|
| 2017 | -21.93M | -2.25M | 121.69M |
| 2018 | -58.34M | -111.63M | 374.82M |
| 2019 | -110.44M | -132.63M | 27.29M |
| 2020 | -127.64M | 100.43M | 26.48M |
| 2021 | -145.12M | 81.35M | 198.45M |
| 2022 | -150.14M | 12.94M | -75.47M |
RUBY Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 227.58M | 92.90M | 93.63M | 309.42M | 104.57M | 7.06M | 1.59M |
Operating activities | |||||||
Net income | -179.66M | -196.54M | -167.73M | -163.45M | -89.19M | -43.84M | -11.01M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 6.25M | 7.72M | 5.69M | 2.99M | 1.26M | 447K | 118K |
Stock-based compensation expense | 15.78M | 35.61M | 33.66M | 41.27M | 27.52M | 17.90M | 147K |
| Deferred income tax benefit | 15.78M | 35.61M | 33.66M | 41.27M | 27.52M | 17.90M | 147K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -9.81M | 5.85M | -1.36M | -1.03M | 4.93M | 1.11M | 589K |
Cash generated by operating activities | -150.14M | -145.12M | -127.64M | -110.44M | -58.34M | -21.93M | -9.50M |
Investing activities | |||||||
Purchases Of Investments | -83.62M | 0 | -122.67M | -319.13M | -160.97M | 0 | 0 |
Investments In Property Plant And Equipment | -5.30M | -3.64M | -5.49M | -40.65M | -14.95M | -2.25M | -443K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 12.94M | 81.35M | 100.43M | -132.63M | -111.63M | -2.25M | -443K |
Financing activities | |||||||
Common Stock Issued | 232K | 188M | 0 | 0 | 257.86M | 100K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -122K | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | -5.5M | 0 | 0 |
Cash used in financing activities | -75.47M | 198.45M | 26.48M | 27.29M | 374.82M | 121.69M | 15.41M |
Net Change In Cash | -212.66M | 134.68M | -732K | -215.78M | 204.84M | 97.50M | 5.47M |
Cash at end of period | 14.91M | 227.58M | 92.90M | 93.63M | 309.42M | 104.57M | 7.06M |
| Data source | Data source | Data source | Data source | Data source |